Money Shifts From Biotech to Pharma as Investors Get Defensive
As expected, health care investors took money out of the risky biotech sector and moved into more defensive drug stocks in Monday trading.
Amgen(AMGN), the largest biotech company, is off $2.88, or 4.5%, to $61.25. Genentech(DNA) is down 71 cents, or 1.5%, to $43.85, Biogen(BGEN) is off $2.76, or 4.6% to $57.55, while Human Genome Sciences (HGSI) is off $3.94, or 9.4%, to $37.65. Idec Pharmaceuticals(IDPH), which had a new cancer drug recommended for approval by an Food and Drug Administration advisory panel on Tuesday, was one of the few biotech stocks to actually trade up when the morning bell rang. Since then, Idec has also drifted lower, falling 1.21 cents to $54.93. Interesting, three companies developing oxygen-carrying human blood substitutes are trading higher, although these stocks have a larger-than-normal retail ownership and volume is relatively low. Biopure(BPUR) is up 7 cents to $21.25, Northfield Laboratories (NFLD) is up 4 cents to $15, and Hemosol (HMSL) is up 19 cents to $2.97. None of the companies have products approved for use in the U.S. Drug stocks are holding their own in today's turbulent market. Merck(MRK) is up $1.03, or 1.5%, to $67.13, Pfizer(PFE) is up 25 cents to $38.42 and American Home Products (AHP) is up $1.51, or 2.6%, to $59.68. Bristol-Myers Squibb(BMY) and Johnson & Johnson(JNJ) are also higher, while Schering-Plough (SGP) is off 66 cents to $36.53.>To order reprints of this article, click here: Reprints
TheStreet Premium Services For Personal Service: 877-471-2967
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 12,855.15 | 1,349.99 | 2,927.17 | 19.74 |
Oil *
118.04
|
|
UP
53.92 |
UP
7.35 |
UP
23.29 |
UP
0.05 |
10 Yr
1.97%
SPDR Gold
167.10
|
|
+0.42%
|
+0.55%
|
+0.80%
|
+0.25%
|
Data delayed 20 minutes |

Connect with TheStreet